BLGO vs. ASPI, LXFR, SLI, ARQ, ADUR, TSE, ZTEK, VGAS, ORGN, and AMTX
Should you be buying BioLargo stock or one of its competitors? The main competitors of BioLargo include ASP Isotopes (ASPI), Luxfer (LXFR), Standard Lithium (SLI), ARQ (ARQ), Aduro Clean Technologies (ADUR), Trinseo (TSE), Zentek (ZTEK), Verde Clean Fuels (VGAS), Origin Materials (ORGN), and Aemetis (AMTX). These companies are all part of the "chemicals" industry.
BioLargo vs.
ASP Isotopes (NASDAQ:ASPI) and BioLargo (NASDAQ:BLGO) are both small-cap basic materials companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability, valuation and community ranking.
ASP Isotopes has a beta of 3.66, indicating that its stock price is 266% more volatile than the S&P 500. Comparatively, BioLargo has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500.
BioLargo has a net margin of -11.45% compared to ASP Isotopes' net margin of -807.39%. BioLargo's return on equity of -39.90% beat ASP Isotopes' return on equity.
BioLargo received 104 more outperform votes than ASP Isotopes when rated by MarketBeat users. However, 100.00% of users gave ASP Isotopes an outperform vote while only 60.99% of users gave BioLargo an outperform vote.
In the previous week, ASP Isotopes had 8 more articles in the media than BioLargo. MarketBeat recorded 8 mentions for ASP Isotopes and 0 mentions for BioLargo. ASP Isotopes' average media sentiment score of 0.47 beat BioLargo's score of 0.00 indicating that ASP Isotopes is being referred to more favorably in the media.
BioLargo has higher revenue and earnings than ASP Isotopes. BioLargo is trading at a lower price-to-earnings ratio than ASP Isotopes, indicating that it is currently the more affordable of the two stocks.
16.8% of ASP Isotopes shares are owned by institutional investors. Comparatively, 0.0% of BioLargo shares are owned by institutional investors. 21.4% of ASP Isotopes shares are owned by company insiders. Comparatively, 20.3% of BioLargo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
ASP Isotopes currently has a consensus price target of $4.50, suggesting a potential upside of 7.66%. Given ASP Isotopes' stronger consensus rating and higher probable upside, analysts plainly believe ASP Isotopes is more favorable than BioLargo.
Summary
ASP Isotopes beats BioLargo on 11 of the 18 factors compared between the two stocks.
Get BioLargo News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLGO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLargo Competitors List
Related Companies and Tools
This page (NASDAQ:BLGO) was last updated on 3/29/2025 by MarketBeat.com Staff
